Lamellar Biomedical is an innovative biotechnology company developing our proprietary LAMELLASOME™ based therapies to transform the treatment of complex and rare lung disorders, either as biologically active products in their own right or by delivering active payloads. Along with our in-house research and development team, we are collaborating with world-renowned institutions and universities to develop therapeutics that capitalise on the unique properties of LAMELLASOME™ formulations that protect lung tissues.
Lamellar’s lead products are:
IPF-Lamellasome: abates pulmonary fibrosis by reducing both myofibroblasts and collagen production. IPF-Lamellasome has the potential to become the first line therapy and the new standard of care in the treatment of Idiopathic Pulmonary Fibrosis (IPF) IPF.
Muco-ease: increases the fluidity of thickened human mucus and may slow disease progression in mild and moderate Cystic Fibrosis (CF) by improving mucociliary clearance
Lamellasome treatment for COVID-19 intended to prevent or mitigate progression of respiratory symptoms to pneumonitis and ARDS, promoting survival ad potentially protecting lungs from fibrotic sequelae of survivors
These therapies are based on LAMELLASOME™ therapies’ abilities to:
Reduce inflammatory responses in pulmonary tissue.
Interrupt the onset and progression of pulmonary inflammation, pneumonitis and the development of fibrosis.
Modulate tissue surface tension, moisture retention and lubrication.
Lamellar’s lead products are:
IPF-Lamellasome: abates pulmonary fibrosis by reducing both myofibroblasts and collagen production. IPF-Lamellasome has the potential to become the first line therapy and the new standard of care in the treatment of Idiopathic Pulmonary Fibrosis (IPF) IPF.
Muco-ease: increases the fluidity of thickened human mucus and may slow disease progression in mild and moderate Cystic Fibrosis (CF) by improving mucociliary clearance
Lamellasome treatment for COVID-19 intended to prevent or mitigate progression of respiratory symptoms to pneumonitis and ARDS, promoting survival ad potentially protecting lungs from fibrotic sequelae of survivors
These therapies are based on LAMELLASOME™ therapies’ abilities to:
Reduce inflammatory responses in pulmonary tissue.
Interrupt the onset and progression of pulmonary inflammation, pneumonitis and the development of fibrosis.
Modulate tissue surface tension, moisture retention and lubrication.
Location: United Kingdom, Scotland, Holytown
Employees: 11-50
Total raised: $7.45M
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | TRI Capita... | tricapital... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.05.2017 | Series C | $7.45M | - |
Mentions in press and media 2
| Date | Title | Description |
| 08.05.2017 | Term Sheet — Monday, May 8 | SWEATER VESTS AND PURSE WARS New York startup SimpleReach has raised new funding and replaced its CEO, founder and former CEO Edward Kim tells Term Sheet. New funding for the “content data platform” startup totals $9 million, led by Spring ... |
| 08.05.2017 | Lamellar Biomedical Raises £5.75M in Series C Funding | Lamellar Biomedical, a Bellshill, Scotland, UK-based biotechnology company developing a range of patent-protected medical and pharmaceutical products, raised £5.75m in Series C equity funding. The round was led by Invesco Asset Management L... |